Wire · regulatory
Unicycive Adds KPM Group to Lobby on Kidney Care
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 November 2026 · Fusion42 review
Unicycive Therapeutics has registered KPM Group DC as a new lobbying firm to support its kidney care and FDA approval advocacy efforts related to its oral phosphate binder drug for chronic kidney disease. This lobbying move accompanies ongoing legislative efforts and CMS payment policy adjustments impacting renal dialysis drugs in the United States.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.
◆ ◆ The Wire takeaway
You can expect kidney care drug approval and reimbursement to become a more politically crowded space with Unicycive's new lobby team. This opens a door to engage on kidney drug policy or anticipate competitive pressure on pricing and market access from bigger lobbying players.
◆ Coverage
1 source · 12 Nov 2026
◆ Related on Wire
◆ Topics